Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin

This article was originally published in The Tan Sheet

Executive Summary

C-reactive protein is significant predictor of cardiac events only in patients not pretreated with aspirin, researchers say in April issue of Journal of the American College of Cardiology. CRP, an inflammatory marker, is an acute-phase reactant in myocardial infarction and unstable angina. Simon Kennon, Bart's and the London NHS Trust, et al., conducted a prospective, cohort study of 304 coronary syndrome patients, 174 of whom were taking aspirin prior to admission. In pretreated patients, "CRP provided no useful information about cardiac risk. [CRP] concentrations tended to be lower...suggesting that the protection aspirin provided against ischemic myocardial injury...attenuated acute-phase inflammatory responses to the point that associations between CRP and ischemic events were lost," authors conclude
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel